Health Care

Twist Bioscience’s insider sales show routine liquidity moves, not a warning—focus on its biotech pipeline, earnings outlook, and market dynamics.

Moderna CFO Mock’s latest insider trade: a fresh buy of 1,454 shares signals confidence amid a 52‑week high, while routine sells show normal liquidity. Discover how insider activity reflects management’s bullish stance on the mRNA leader.

Inside SOPHiA Genetics’ October 5 insider sales: a tax‑planning move, not panic, showing exec confidence and long‑term growth outlook.

CEO Aslan Fred sells 23,463 Artiva Biotherapeutics shares at $7.20, a routine tax‑cover move that shows stable insider activity and modest impact on stock.

George Milne’s October 5 sale of 30,000 Amylyx shares at $27.70 shows routine insider profit‑taking amid a 19% yearly rise, indicating stable confidence in the ALS biotech’s pipeline.

Alignment Healthcare’s recent insider selling shows tax‑driven moves, not a crisis. Learn how the company’s continuous‑care platform and solid pipeline could still offer a margin of safety for value‑focused investors.

Insider sales at EMERGENT BIOSOLUTIONS are routine tax‑planning moves—no distress signals, just modest 10b5‑1 trades as the stock climbs on a strong pipeline.

Insider buying surge at AgomAb Therapeutics shows exec confidence amid a steep decline – a unique chance for value investors to gauge upside potential.

CEO of AGOMAB THERAPEUTICS buys shares amid stock slump, signaling confidence in pipeline and potential rebound—investors should watch upcoming trials.

GIC’s recent sell‑offs of MEDLINE Inc. shares signal routine portfolio rebalancing, not a downgrade, underscoring the company’s solid fundamentals and investor confidence.